In a patient with hypogonadotropic hypogonadism and hypertension, what is the likely cause and which diagnostic test should be performed next?

Hypertension in Hypogonadotropic Hypogonadism: Cause and Next Test

In a patient with hypogonadotropic hypogonadism and hypertension, screen immediately for primary aldosteronism by measuring paired plasma aldosterone concentration and plasma renin activity (or direct renin concentration) to calculate the aldosterone-to-renin ratio (ARR).

Why Primary Aldosteronism Should Be Your Primary Concern

The combination of hypogonadotropic hypogonadism with hypertension raises significant concern for primary aldosteronism (PA), which is the most common cause of secondary hypertension, affecting 5-14% of hypertensive patients in primary care and up to 30% in referral centers 1. This is critically important because PA carries substantially higher cardiovascular risk than essential hypertension and is potentially curable or specifically treatable 2, 1.

The Metabolic-Endocrine Connection

Hypogonadotropic hypogonadism frequently coexists with metabolic syndrome, obesity, and insulin resistance 3. These same conditions are associated with increased prevalence of PA. The inflammatory state linking insulin resistance to hypogonadotropic hypogonadism 3 may also predispose to adrenal dysfunction. This metabolic overlap makes PA screening essential in your patient.

Diagnostic Algorithm

Step 1: Initial Screening Test (Do This Now)

Measure simultaneously:

• Plasma aldosterone concentration (PAC)
• Plasma renin activity (PRA) or direct renin concentration
• Serum potassium (to aid interpretation, though hypokalemia is present in only a minority of PA cases early on) 4

Calculate the aldosterone-to-renin ratio (ARR):

• ARR > 30 (when using conventional units) suggests autonomous aldosterone secretion 5
• ARR > 1400 pmol/L/ng/mL/h (or > 270 pmol/L/ng/L) with PAC > 440 pmol/L is highly suggestive 2

Critical caveat: Many medications interfere with this test. Ideally withdraw:

• Mineralocorticoid receptor antagonists (spironolactone, eplerenone) for 4-6 weeks
• Diuretics, ACE inhibitors, ARBs for 2 weeks
• Beta-blockers if possible

Continue alpha-1 blockers, non-dihydropyridine calcium channel blockers, or hydralazine for blood pressure control during testing 6.

Step 2: If ARR is Elevated

Confirmatory testing is required unless PAC > 550 pmol/L (200 pg/mL) with suppressed renin and spontaneous hypokalemia—this triad confirms PA without further testing 6.

Choose one confirmatory test 2, 7:

1. Intravenous saline infusion test (most commonly used):

   • Infuse 2L normal saline over 4 hours
   • PA confirmed if post-infusion PAC > 280 pmol/L
   • PA unlikely if < 140 pmol/L

2. Oral sodium loading test:

   • 200 mmol/day sodium for 3 days

   • Measure 24-hour urinary aldosterone on day 3-4
   • PA confirmed if urinary aldosterone > 33 nmol/day

3. Captopril suppression test:

   • 25-50 mg captopril after 1 hour sitting/standing
   • Measure aldosterone at baseline and 1-2 hours post-dose
   • PA unlikely if aldosterone suppresses >30%

4. Fludrocortisone suppression test (most sensitive but burdensome):

   • Requires hospitalization
   • Monitor for severe hypokalemia

Important: Correct hypokalemia before any confirmatory testing to avoid false negatives 6.

Step 3: If PA is Confirmed

Proceed to subtype classification to distinguish unilateral (potentially surgical) from bilateral disease:

1. Adrenal CT scan (3mm cuts) as initial imaging 2, 4
2. Adrenal vein sampling (AVS) if surgery is considered—this is essential because CT alone leads to unnecessary adrenalectomy in 25% of cases due to non-functioning adenomas 4

Additional Screening Considerations

While PA is the priority, also screen for:

Pheochromocytoma

Less likely but potentially life-threatening. Screen if patient has:

• Paroxysmal hypertension with headache, sweating, palpitations, pallor
• Resistant hypertension
• Adrenal incidentaloma

Test: 24-hour urinary fractionated metanephrines (sensitivity 95-100%) or plasma free metanephrines 4, 8.

Cushing's Syndrome

Consider if patient has:

• Central obesity, striae, easy bruising, proximal muscle weakness
• Difficult-to-control hypertension

Test: 1-mg overnight dexamethasone suppression test (cortisol should suppress to <1.8 mcg/dL) 9.

Why This Matters for Morbidity and Mortality

PA is not just about blood pressure—it causes:

• Excess cardiovascular disease independent of BP elevation 1
• Renal injury beyond that seen in essential hypertension 2
• Increased risk of stroke and atrial fibrillation 1

Treatment dramatically improves outcomes:

• Unilateral disease: Adrenalectomy can cure hypertension
• Bilateral disease: Mineralocorticoid receptor antagonists (spironolactone 25-50 mg daily) effectively control BP and reduce cardiovascular risk 2

Common Pitfalls to Avoid

1. Don't assume hypokalemia is required for PA—70% of PA patients are normokalemic at presentation 4
2. Don't skip confirmatory testing (except in the specific scenario noted above)—ARR alone has too many false positives
3. Don't proceed to surgery based on CT alone—always perform AVS first 2, 4
4. Don't forget to monitor renal function after treatment—unmasking of underlying kidney disease can occur as hyperfiltration resolves 2

Addressing the Hypogonadotropic Hypogonadism

Once you've ruled out/treated secondary hypertension:

• Evaluate for reversible causes: obesity, medications (opioids, glucocorticoids), systemic illness 10, 3
• Screen for other pituitary hormone deficiencies and pituitary/hypothalamic lesions with MRI if organic cause suspected 11, 12
• Consider testosterone replacement only after fertility assessment if desired, as it will suppress spermatogenesis 13, 10

The hypogonadotropic hypogonadism may be "functional" related to metabolic syndrome and could improve with weight loss and treatment of the underlying metabolic disorder 3, 14.